Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 09-2015 | 06-2015 | 03-2015 | 12-2014 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,259 | 4,380 | 601 | 177 | 207 |
| Other current assets | 36 | 31 | 32 | 32 | 37 |
| TOTAL | $3,454 | $4,507 | $786 | $431 | $308 |
| Non-Current Assets | |||||
| PPE Net | 13 | 16 | 17 | 19 | 21 |
| Other Non-Current Assets | 44 | 19 | 19 | 19 | 19 |
| TOTAL | $57 | $35 | $35 | $38 | $40 |
| Total Assets | $3,511 | $4,542 | $821 | $469 | $348 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 125 | 132 | 286 | 388 | 410 |
| Accrued Expenses | 372 | 412 | 306 | 267 | 291 |
| Other current liabilities | 84 | 76 | 1,088 | 150 | 100 |
| TOTAL | $582 | $620 | $1,679 | $806 | $801 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 2,455 | 4,513 | 2 | 2 | 0 |
| TOTAL | $2,458 | $4,516 | $2 | $2 | $1 |
| Total Liabilities | $3,040 | $5,136 | $1,682 | $807 | $802 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 80 | 77 | 65 | 65 | 65 |
| Common Shares | 20 | 18 | 16 | 16 | 16 |
| Retained earnings | -7,759 | -7,067 | -5,885 | -3,828 | -2,917 |
| Other shareholders' equity | 2,123 | 731 | 687 | 190 | 190 |
| TOTAL | $471 | $-594 | $-861 | $-338 | $-454 |
| Total Liabilities And Equity | $3,511 | $4,542 | $821 | $469 | $348 |